相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma
Hiroaki Kanzaki et al.
SCIENTIFIC REPORTS (2021)
Novel Pyridine Bioisostere of Cabozantinib as a Potent c-Met Kinase Inhibitor: Synthesis and Anti-Tumor Activity against Hepatocellular Carcinoma
Ujjwala Karmacharya et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Synthesis and anti-hepatocellular carcinoma activity of aminopyridinol-sorafenib hybrids
Bhuwan Prasad Awasthi et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2021)
Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma
Haibo Liu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma
Renata Rezende Miranda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4
Xiaojing Lin et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life
Daneng Li et al.
CANCERS (2019)
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Andreas Weiss et al.
MOLECULAR CANCER THERAPEUTICS (2019)
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D. Kim et al.
CANCER DISCOVERY (2019)
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Roberta Zappasodi et al.
CANCER CELL (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Role of fibroblast growth factor receptor 4 in cancer
Shuya Tang et al.
CANCER SCIENCE (2018)
Making way for suppressing the FGF19/FGFR4 axis in cancer
Nestor Prieto-Dominguez et al.
FUTURE MEDICINAL CHEMISTRY (2018)
2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors
Cheng Mo et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas
Xiaochen Zhang et al.
THORACIC CANCER (2017)
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Jaya Julie Joshi et al.
CANCER RESEARCH (2017)
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study
Tom M. Ganten et al.
CLINICAL CANCER RESEARCH (2017)
Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping
Yikai Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten et al.
CLINICAL CANCER RESEARCH (2016)
FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β-catenin signaling cascade via FGFR4 activation
Huakan Zhao et al.
ONCOTARGET (2016)
Selectivity of the complexation reactions of four regioisomeric methylcamphorquinoxaline ligands with gold(III): X-ray, NMR and DFT investigations
Biljana D. Glisic et al.
POLYHEDRON (2016)
Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival
Kai Hung Tiong et al.
ONCOTARGET (2016)
FGFR4 Is a Potential Predictive Biomarker in Oral and Oropharyngeal Squamous Cell Carcinoma
Koos Koole et al.
PATHOBIOLOGY (2015)
Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents
Leisl M. Packer et al.
CANCER DISCOVERY (2015)
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
Margit Hagel et al.
CANCER DISCOVERY (2015)
6-Amino-2,4,5-trimethylpyridin-3-ols: A new general synthetic route and antiangiogenic activity
Dong-Guk Kim et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Vito Guagnano et al.
CANCER DISCOVERY (2012)
Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening
Eric T. Sawey et al.
CANCER CELL (2011)
Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
Vito Guagnano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention
Han Kiat Ho et al.
JOURNAL OF HEPATOLOGY (2009)
Lead Finder: An Approach To Improve Accuracy of Protein-Ligand Docking, Binding Energy Estimation, and Virtual Screening
Oleg V. Stroganov et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2008)
Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer
B Gowardhan et al.
BRITISH JOURNAL OF CANCER (2005)
Bioisosterism: A useful strategy for molecular modification and drug design
LMA Lima et al.
CURRENT MEDICINAL CHEMISTRY (2005)
A convenient synthesis of 14C-labelled resveratrol
DL Zeng et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2004)
High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells
X Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
